DEF: AngioDynamics Sets Annual Meeting, Proposes Director Elections

AngioDynamics, Inc. has announced its 2026 Annual Meeting of Shareholders, scheduled for November 17, 2026, to address director elections, auditor ratification, executive compensation, and equity plan amendments.

Summary

• AngioDynamics, Inc. is holding its Annual Meeting of Shareholders virtually on November 17, 2026.
• Key proposals include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2027, an advisory vote on executive compensation, and an amendment to increase shares available under the 2020 Equity Incentive Plan.
• Shareholders of record as of September 18, 2026, are eligible to vote.
• The company is utilizing a "notice and access" model for proxy materials, providing them online to reduce costs and environmental impact.
• James C. Clemmer, the current CEO, is retiring effective November 2, 2026, and will be succeeded by Eric Honroth.
• The company's fiscal year ended May 31, 2026, saw a 9.5% revenue increase to $320.2 million, with Med Tech growing 18.4% and Med Device growing 2.6%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily focused on procedural matters for the upcoming annual shareholder meeting and standard corporate governance updates.

Positives

• Revenue increased by 9.5% to $320.2 million for the fiscal year ended May 31, 2026.
• The Med Tech segment showed strong growth of 18.4% in fiscal year 2026.
• Gross margin increased by 70 basis points to 54.6% in fiscal year 2026.
• The company maintains a strong governance structure with 7 out of 8 directors being independent.
• Robust stock ownership guidelines are in place for executives and directors to align interests with shareholders.
• The company has a clawback policy to recoup incentive-based compensation in cases of fraud or misconduct.

Negatives

• Net loss increased by $2.7 million to $36.7 million for the fiscal year ended May 31, 2026.
• Loss per share increased by $0.05 to $0.88 for the fiscal year ended May 31, 2026.

Risks

• Forward-looking statements are subject to risks and uncertainties; refer to Form 10-K for detailed risk factors.
• The company operates in a competitive industry with global macroeconomic conditions impacting its business, including inflationary pressures and consumer demand disruptions.
• The amendment to the 2020 Equity Incentive Plan, if approved, would increase potential dilution to approximately 17.2% on a fully-diluted basis.

Future Outlook

The company believes its strategic research & development and sales & marketing investments in growth platforms position it well for fiscal year 2027. The proposed amendment to the 2020 Equity Incentive Plan is intended to provide sufficient shares for equity-based compensation needs for approximately two years following shareholder approval.

Management Comments

• "For the year ended May 31, 2026, on a GAAP as reported basis, our revenue increased 9.5%. Our Med Tech business... grew 18.4% in fiscal year 2026, driven by growth across all product lines."
• "Despite these persistent challenges, we made significant progress in our transformation into a customer-focused, technology-driven, growth-oriented company."
• "We believe that increasing the 2020 Plan share reserve by 1,000,000 would provide sufficient shares for the Company's equity-based compensation needs for approximately two years following shareholder approval."

Industry Context

StockSavvy.ai notes that AngioDynamics is operating within the competitive medical device sector, facing typical industry challenges such as macroeconomic pressures. The company's strategic focus on its Med Tech and Med Device platforms aligns with industry trends towards specialized, high-growth technology areas.

Comparison to Industry Standards

• The compensation peer group for fiscal year 2026 includes 16 publicly-traded medical device companies with revenues ranging from approximately one-third to three times AngioDynamics' current revenue.
• The company targets executive compensation within a competitive range of the 50th percentile of this peer group.
• Performance share awards are measured against a peer group of 47 publicly traded healthcare equipment companies for relative Total Shareholder Return (TSR) assessment.

Management Changes

Corporate Governance

Related Party Transactions

• No related party transactions occurred during the fiscal year ended May 31, 2026.
• The company has a Related Person Transaction Policy requiring pre-approval by the Audit Committee for transactions exceeding $50,000 where related persons have a material interest.

Stakeholder Impact

• Shareholders will vote on director elections, auditor ratification, executive compensation, and equity plan amendments.
• Employees and executives will be impacted by the proposed increase in shares available under the equity incentive plan.
• The transition in CEO leadership may impact employee morale and strategic direction.

Next Steps

• Shareholders are encouraged to vote their shares promptly for the proposals presented at the Annual Meeting.
• The company will announce preliminary voting results at the Annual Meeting and file final results on Form 8-K within four business days.
• The proposed amendment to the 2020 Equity Incentive Plan requires shareholder approval at the Annual Meeting.

Key Dates

Recommendation

The filing is primarily procedural, related to the annual shareholder meeting and standard corporate governance matters. While there is revenue growth, the increased net loss and the procedural nature of the filing do not provide strong indicators for a buy or sell recommendation at this time. A 'hold' reflects the neutral to slightly positive sentiment and the lack of significant new strategic or financial developments.

Keywords

Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Equity Incentive Plan, Auditor Ratification, Corporate Governance, Shareholder Vote